Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Ann Rheum Dis. 2018 Nov 8;78(1):122–130. doi: 10.1136/annrheumdis-2018-213708

Figure 1.

Figure 1.

Time death (Figure 1a) and time to death or organ failure (Figure 1b) from randomization in SLS I. There was no significant difference in the time to death (p=0.335 by log-rank test; Figure 1a), nor the time to death or organ failure (p=0. 539 by log-rank test; Figure 1b) for patients randomized to CYC versus placebo in SLS I. The last known date they were known to be alive was used for the survival analysis.